Home › Conferences › CTAD
Clinical Trials on Alzheimer's Disease 2026
Nov 16-19, 2026 · Boston, US · Neuro - Alzheimer's.
DatesNov 16-19, 2026
LocationBoston, US
Therapeutic focusNeuro - Alzheimer's
Biotech presenters tracked1
Biotech presenters
Presenter history
We have tracked 2 biotech presentations by 2 companies across 1 past CTAD meeting (2024-2024). Upcoming presenters populate as abstracts are released. See the conference run-up study for how these names behaved into the meeting.
About · Corrections · Changelog · Glossary · Methodology
Not affiliated with CTAD or its organizer. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.
© 2026 pdufa.bio. All rights reserved.
Not affiliated with CTAD or its organizer. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.
© 2026 pdufa.bio. All rights reserved.
How CTAD stocks have traded historically
Median share-price move around a presentation, measured across 1425 all tracked conference presentations in our study (2017-2026), because our study holds fewer than 12 CTAD events on their own.
30 days before-0.03% 50% rose · n=1425
10 days before+0.63% 52% rose · n=1425
Presentation day-0.56% 44% rose · n=1425
5 days after-1.59% 39% rose · n=1425
10 days after-1.93% 40% rose · n=1425
Read the whole row, not just the first line: across this study stocks have drifted up into these meetings and down out of them, and the effect is largest in the smallest companies. Medians are shown because a handful of large moves pulls an average away from the typical case. This is a historical distribution for a cohort of companies, not a forecast for any single company, and not investment advice. Methodology and the full study.
FAQ
When is CTAD 2026?
Clinical Trials on Alzheimer's Disease 2026 runs November 16-19, 2026 in Boston, US. The date comes from the organiser's own announcement; check the organiser's site for the final programme.
Which biotech companies are presenting at CTAD 2026?
From company filings and releases we have sourced 1 presenter commitment for this edition: CRVO. This is not the organiser's programme -- only presentations companies have themselves announced, each linked to its filing on the conferences page.
Why do medical conference dates matter for biotech stocks?
Trial results are often presented first at medical meetings, so a company's announced presentation is a dated, public catalyst. We publish a study of how biotech stocks have historically traded into conference presentations on the research page; it is historical measurement, not a prediction, and none of this is investment advice.